Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263)
Koike T, Miyamoto M, Nishi T, Sunahara E, Hasegawa S, Watanabe S, Ikeda S, Ishii T, Kondo S, Takahashi J, Hirabayashi H, Alagille D, Barret O, Tamagnan G, Kuroita T. Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p5.263.Peer-Reviewed Original Research